To provide the information your oncologist is not telling you or doesn't have the time to!
The treatment landscape for advanced-stage classic Hodgkin’s lymphoma (cHL) is rapidly evolving. Traditionally, chemotherapy regimens such as AVD (doxorubicin, vinblastine, dacarbazine) or combinations including brentuximab vedotin have been used to manage this challenging disease. However, a groundbreaking phase 3 clinical trial (S1826) has introduced a promising new regimen—nivolumab (N+AVD)—that is proving to be superior in …
The medical community continues to explore groundbreaking treatments in the fight against cancer, with CAR-T therapy standing out for its innovative approach. This treatment, involving the genetic modification of a patient’s T cells to target cancer cells, has provided new avenues for those battling certain blood cancers. Here, we delve into the essence of CAR-T …
Empowering Hope: A Breakthrough in CLL/SLL Treatment On December 1, 2023, the Food and Drug Administration (FDA) delivered a beacon of hope by granting accelerated approval to pirtobrutinib (Jaypirca, Eli Lilly and Company). This approval is a significant stride in the treatment landscape for adults facing chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) …